SensArs coordinates a consortium of 4 partners coming from 4 countries to take to market its product SENSY

SensArs Neuroprosthetics coordinates a 3 million EUR grant to develop and test its product that restores life-like sensations from the prosthesis of leg amputees

 

SensArs Neuroprosthetics announces the start of a project financed by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 870144.

The European Commission will give a total amount of 3 million to SensArs Neuroprosthetics, the coordinator, Ossur, the 2nd largest prosthesis manufacturer worldwide, Gemelli Policlinic of Rome and Charité of Berlin, two clinical centers.

During the project, SensArs will finalize its product that restores touch and movement sensations from the prosthesis of leg amputees, by stimulating their sciatic nerve through tiny implanted electrodes. Ossur will provide its great experience in prosthetics to assure the product will match the requirements of the final users, the amputees.

The product will then be tested with patients in the two clinical centers in Germany and Italy.

The project can be consulted on the European Commission portal at: https://cordis.europa.eu/project/rcn/224965/factsheet/en

SensArs has recently made public on Nature Medicine and Science Translational Medicine, the results of a pilot trial with leg amputees testing the first prototype of the product. More details can be found at https://www.nature.com/articles/s41591-019-0567-3 and https://stm.sciencemag.org/content/11/512/eaav8939. Patients, thanks to the prosthesis with sensations, walked faster with less body and mental fatigue, and reduced the risk of falls. Phantom limb pain was also decreased or eliminated by nerve stimulation.

Francesco Petrini, Co-founder and CEO of SensArs Neuroprosthetics, says: “after the encouraging results of the pilot trial with our first prototype, now the GoSafe project will allow us to make the technology fully implantable and portable for a clinical trial that will finally show the complete safety of technology and benefits for the patients”

Clinical results are expected in 2022.